Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • HM43239 for AML
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • HM43239 for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Careers
  • Contact

Presentations

News

News

  • Press Releases
  • Presentations
  • Events
Aptose Corporate Presentation March 2022

Aptose Corporate Presentation March 2022

Mar 15, 2022
Aptose Corporate Update at ASH 2021

Aptose Corporate Update at ASH 2021

Dec 13, 2021
2021 ASH Poster - A Phase 1a/b Study of APTO-253 in R/R AML and HR-MDS

2021 ASH Poster - A Phase 1a/b Study of APTO-253 in R/R AML and HR-MDS

Dec 13, 2021
2021 ASH Presentation - A Phase 1/2 Study of HM43239 in R/R AML

2021 ASH Presentation - A Phase 1/2 Study of HM43239 in R/R AML

Dec 13, 2021
2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R AML

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R AML

Dec 11, 2021
2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R B-Cell Malignancies

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R B-Cell Malignancies

Dec 11, 2021
Aptose Corporate Update at EHA 2021

Aptose Corporate Update at EHA 2021

Jun 11, 2021
2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in R/R B-Cell Malignancies

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in R/R B-Cell Malignancies

Jun 11, 2021
2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in R/R AML or HR MDS

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in R/R AML or HR MDS

Jun 11, 2021
Aptose Corporate Update at ASH 2020

Aptose Corporate Update at ASH 2020

Dec 6, 2020
RSS
  • 1
  • 2
  • 3
  • 4
  • Next »
© 2022 Aptose Biosciences Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap